Skip to main content


Scientific Name(s): Emblica officinalis Gaertn., Phyllanthus emblica L.
Common Name(s): Amalakam, Amalaki, Amla, Amlabaum, Amlaj, Amulch, An mole, Anwala churna, Chyavanprash, Emblic myrobalan, Gebrau chilicher, Hyponidd, Indian gooseberry, Kalpaamruthaa, Nelli, Ngop, Shabju, Sriphalam, Toppinelli, Triphala, Yeowkan tse, Ziphiyu-si

Medically reviewed by Last updated on Jun 20, 2022.

Clinical Overview


Data support benefit of emblica supplementation in dyslipidemic patients as well as antioxidant and anti-inflammatory activity. There is limited robust clinical evidence to support the use of emblica for any other indication.


There are few clinical studies to guide dosages. Diabetes/hyperlipidemia: 1 to 3 g of powdered, dried fruit was consumed daily in 30 mL of water for 21 days in 1 clinical trial. Another trial used amla 300 mg tablets (each containing 50% amla extract and 50% dextrin) 3 times per day. Hypercholesterolemia/hyperlipidemia: 500 mg standardized extract of Phyllanthus embilica twice daily.


Contraindications have not been identified.


Information regarding safety and efficacy in pregnancy and lactation is lacking.


None well documented.

Adverse Reactions

Research reveals little or no information regarding adverse reactions with the use of this product.


No major toxicities have been reported.

Scientific Family

  • Euphorbiaceae


Emblica is a small to medium-sized deciduous tree native to tropical southeastern Asia. Its leaves are simple, feather-like, and closely set along the branchlets. Flowers are green-yellow, and the round, greenish-yellow fruits are smooth and hard in appearance. The fruits, which ripen in autumn and are harvested by hand, are commonly used in the Indian diet.1, 2, 3 A common synonym is Emblica officinalis Gaertn.


A method of emblica preparation was described in the first century AD in Sanskrit. Records of the medicinal use of emblica also have been found in Arabic, Tibetan, and Egyptian texts, as well as in the Sidha (Indian), Ayurvedic, and Unani systems of medicine. All parts of the plant including the fruit, seed, leaves, root, bark, and flowers are used in both dried and fresh forms. In the Ayurvedic system, the amla fruit is noted for its light and dry qualities, as well as being cooling in energy. In India, the fruit is commonly eaten as a pickle.2, 3


The fruits contain a high concentration of ascorbic acid, which degrades with heating or cooking. In addition, they contain phenols, including ellagic acid, gallic acid, quercetin, kaempferol, corilagin, geraniin, furosin, gallotanins, emblicanins, flavonoids, glycosides, and proanthocyanidins.4, 5, 6, 7, 8, 9, 10 The roots contain glycosides and tannins.11, 12

Most of the properties assigned to emblica are attributed to its strong antioxidant action.8, 13, 14, 15, 16 The ascorbic acid content of the fruit has been assayed at approximately 1 g per 100 mL of fresh fruit juice and accounts for 45% to 70% of the antioxidant activity.17 The Ayurvedic process of preparing the amla berry results in a 3-fold increase of ascorbic acid and an increase in the concentration of polyphenols. This dried fruit powder is mixed with fresh emblica juice for a few hours, and then dried and powdered again. Repeated up to 21 times, this method of fruit processing is nutritionally beneficial.17 Other compounds having antioxidant properties include the emblicanins, gallic acid, methyl gallate, corilagin, furosin, and geraniin.6, 17, 18

Uses and Pharmacology

Few quality controlled clinical trials are documented despite the widespread use of emblica in traditional health systems.


Alcohol and aqueous extracts of emblica fruit were tested for analgesic and antipyretic activity in mice. Results were similar to those of aspirin, except for response to heat pain model in which emblica had no activity.83

Anti-inflammatory effects

Animal and in vitro data

Animal models of acute and chronic inflammation show limited anti-inflammatory effects, with reduced edema and granulomatous tissue at higher dosages.19, 20 In vitro studies using bronchial epithelial cells extracted from a patient with cystic fibrosis demonstrated inhibition of pro-inflammatory cytokine expression.21 Inhibition of collagenase and hyaluronidase by dried emblica fruit extract using donor cartilage from osteoarthritic patients were also demonstrated in vitro.22 Crude extracts have also induced apoptotic cell death of mature osteoclasts without affecting osteoclastogenesis, possibly via modulation of transcription factors.23, 24

Clinical data

A significant decrease was reported in high-sensitivity C-reactive protein levels (P<0.001) compared with baseline in obese (body mass index [BMI] 25 to 35) adults following 12 weeks supplementation of a standardized P. embilica extract (CAPROS) 500 mg twice daily.94 Similar improvements in hs-CRP were observed with CAPROS 250 mg and 500 mg given for 12 weeks, with the 500 mg dose performing significantly better than the lower dose (P<0.05) in another double-blind, randomized, placebo-controlled study that enrolled 59 patients with metabolic syndrome and confirmed endothelial dysfunction.98

Antimicrobial effects

Animal data

Induced Klebsiella pneumoniae in mice responded in the long term (30 days) to dietary supplementation with powdered fruit. However, colonization was not prevented in the short term (15 days).32 Alcoholic and aqueous extracts of emblica showed positive results against common human pathogens, including bacteria, viruses, and fungi. Activity appears to be stronger against gram-positive bacteria, and only limited efficacy against fungi.25, 26, 27, 28 Activity against herpes simplex viruses 1 and 2 has been attributed to the phenolic content29 while activity against the coxsackie virus was found for phyllaemblicin B extracted from the roots of the plant.30, 31

Clinical data

Total oral bacteria as well as levels of Streptococcus mutans and Porphyromonas gingivalis were significantly reduced after chewing 10% emblica fruit extract gum when compared to baseline and placebo in a single-blind, randomized, placebo-controlled cross-over in 20 healthy volunteers.95

In patients with chronic periodontitis, an infectious disease that results in inflammatory degradation of tissues that support the teeth, subgingival application of 10% emblica sustained-release gel as an adjunct to scaling and root planing produced significantly greater improvements in several periodontal parameters at 3 months compared to placebo enrolled in a double-blind, randomized, placebo-controlled study (N=46).96


An alcoholic extract of the fruits showed a dose-dependent effect similar to that of dropropizine in cats, but was less active than codeine.84


An alcoholic extract of emblica roots showed neutralizing capacity against the hemorrhagic action of snake venom in mice.85


Much interest surrounds the potential for emblica use in treating cancer; however, there are no published clinical trials or epidemiological data.

Animal data

In response to heavy metal carcinogens (arsenic, chromium, nickel), rats given emblica extracts showed a reduction in the number of chromosomal aberrations, number of damaged cells, frequency of micronuclei in bone marrow cells, free radical production, and increased cell survival.33, 34, 35, 36 Rodents fed emblica extracts showed an increase in activity of natural killer cells, antibody-dependent cellular cytotoxicity, and survival in response to tumor cells (lymphoma and mammary carcinoma).37, 38, 39 In 1 of these experiments, there was no effect on tumor development, but a decrease in tumor volume was shown.33 Cytotoxicity to tumor cells has been demonstrated by organic acid gallates and hydrolysable tannins.7 One report has been published in which emblica had no effect in reducing lung cancer parameters in mice.40 Emblica extracts protected irradiated mice from radiation sickness, increased the 30-day survival rate, and decreased total mortality.41, 42, 43

Clinical data

Research reveals no clinical trial data regarding the use of emblica in cancerous conditions. However, in vitro studies using human cancer cell lines including lung, liver, cervical, ovarian, and breast cells have been conducted.44, 45, 46, 47 Various extracts of emblica inhibited hepatocarcinogenesis as measured by parameters such as tumor incidence, enzyme measurements, and other liver injury markers.37, 48, 49, 50, 51

Cardiac effects

The emblica fruits showed a protective effect against ischemic reperfusion injury in rats.86 In another study, the emblicanins were demonstrated to prevent oxidative stress.9


Studies in rats have demonstrated improved memory and reversal of drug-induced amnesia with the Ayurvedic preparation anwala churna.87, 88 Aqueous fruit extract exerted a protective effect on alcohol-induced brain mitochondrial dysfunction in rats.89


Animal data

Animal experiments have been conducted, as well as in vitro studies using human skin fibroblasts demonstrating increased cell proliferation and collagen production at wound and ultraviolet B light (UBV) photo-aged sites.52, 53, 54

Clinical data

Limited clinical studies have been conducted using emblica extracts in combination with other agents in skin-lightening creams as an alternative to hydroquinone.55


Animal data

In single- and multidose experiments, emblica decreased blood glucose levels in rats with an induced diabetic state.13, 14, 15, 73Triphala (a mixed herbal preparation containing emblica) showed a stronger effect than emblica alone79 and another mixed preparation reduced blood glucose in a manner similar to that of glibenclamide.14 Serum creatinine was reduced, and serum albumin increased within 20 days in rats fed emblica.14 In rats with induced diabetes, neuropathic pain was reduced with supplemental emblica possibly via an antioxidative mechanism.80 In vitro studies also suggest inhibition of alpha-amylase and glucosidase as potential mechanisms.81 However, in another study in rats with diabetes, dried fruits did not prevent hyperglycemia despite delaying cataract progression.82

Clinical data

Decreases in fasting and 2-hour postprandial serum glucose were demonstrated in a clinical study using both healthy and type 2 diabetic volunteers. One to 3 g of powdered, dried fruit was consumed daily in 30 mL of water for 21 days.78 In another study in patients with ESRD and uremia, no effect on diabetic indices was observed.72

GI effects

Animal data

Alcoholic and aqueous extracts of emblica have shown protective and healing effects in induced gastric ulcers in animal experiments.56, 57, 58 One experiment, however, established a biphasic effect with healing observed at lower doses of ethanolic fruit extracts and ulceration evident on histology with higher doses.59

In vitro studies using rodent jejunum and ileum as well as in live mice show antidiarrheal and spasmolytic effects on castor oil-induced diarrhea, possibly due to muscarinic action and calcium channel blockade.60

Clinical data

Research reveals no clinical data regarding the use of emblica in gastric ulcers or diarrhea.

Hepato- and renal-protective effects

Animal data

Alcoholic and aqueous extracts of emblica fruits have shown hepatoprotective properties in experiments in rats. Hepatic insults include antituberculosis drugs, arsenic, ethanol, thiacetamide, carbon tetrachloride, and cyclophosphamide. The experiments demonstrated histological and/or enzymatic protective and restorative effects. A decreased severity of hepatic fibrosis was also demonstrated, and some studies included improved renal and pancreatic indices.61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71

Clinical data

Research reveals no clinical data regarding the use of emblica in renal disease; however, in patients with uremia consequent to end-stage renal disease (ESRD), emblica reduced markers of oxidative stress. No effect on hepatic, renal, or diabetic indices was observed.72


Animal data

A number of animal experiments report improved lipid profiles.73, 74, 75 Flavonoid extracts from the fruits of emblica inhibited synthesis and enhanced degradation of cholesterol via increased hepatic HMG-CoA reductase.10 Fresh emblica fruit juice administered to rabbits resulted in induced aortic plaques regressing to near normal, while serum and tissue lipids decreased76 and ethanol extract of emblica improved the lipid profile, as well as reduced hypertension in induced metabolic syndrome in rats.74

Clinical data

In a human clinical trial, healthy and hypercholesterolemic men (35 to 55 years of age) given emblica supplementation for 28 days experienced a decrease in serum cholesterol levels. The condition was reversible upon discontinuation of the supplement.77 Similar results were observed in dyslipidemic adults given emblica extract 500 mg/day for 12 weeks plus lifestyle advice in a double-blind, randomized, placebo-controlled trial (N=98). Based on data presented in tables (which were not fully congruent with results summarized in text), triglycerides (P=0.0003), total cholesterol (P=0.0003), low-density lipoprotein (LDL) (P=0.0064), high-density lipoprotein (HDL) (P=0.0149), very LDL (P=0.0001), and atherogenic index of plasma (P=0.0177) were significantly improved with emblica compared to placebo. Whereas ApoB:ApoA1 was significantly improved only within the emblica group and no significant changes were seen between groups for CoQ10, homocysteine, thyroid-stimulating hormone, and fasting blood glucose.97 In volunteers with and without type 2 diabetes, 2 to 3 g daily of powdered, dried emblica fruit improved the lipid profile (decreased total cholesterol, LDL, and triglycerides; increased HDL) at 21 days. Only among the volunteers with diabetes was there a decrease in total lipids at the 3 g daily dose.78 In obese (BMI 25 to 35) adults not on statin therapy, significant decreases in calculated LDL-cholesterol (P=0.023) and total cholesterol/HDL (P=0.006) compared with baseline were seen following 12 weeks supplementation of a standardized P. embilica extract (CAPROS) 500 mg twice daily.94 Supplementation with CAPROS 250 and 500 mg twice daily for 12 weeks significantly improved endothelial function and all lipid parameters. Oxidative stress and systemic inflammatory biomarkers significantly improved, as well, compared to placebo (P<0.001 for each dose, except P<0.05 for HDL at 250 mg), with the 500 mg dose performing significantly better than the lower dose (P<0.05) in another double-blind, randomized, placebo-controlled study that enrolled 59 patients with metabolic syndrome and confirmed endothelial dysfunction.97


Rats exposed to noise stress for 15 days and given Triphala showed an increased neutrophil function and lowered cortisone release.90 However, in another experiment, an aqueous extract of emblica fruits had no effect on cold stress-induced cortisone release.91


Emblica is one component of a mixed herbal eye drop formulation (Ophthacare) that showed activity in mild infections and inflammatory eye conditions in a clinical study; however, the quality of study methodology was limited.92

Oral microbiome

Chewing 10% emblica fruit extract sugar-free gum was found to significantly increase salivary flow during the first 10 minutes and significantly reduce malodorous compounds after 15 minutes compared to placebo in 20 healthy volunteers. Additionally, total bacteria as well as levels of Streptococcus mutans and Porphyromonas gingivalis were significantly reduced when compared to baseline and placebo in this single-blind, randomized, placebo-controlled crossover.95

Platelet aggregation

ADP- and collagen-induced platelet aggregation were significantly down-regulated compared with baseline following 12 weeks of supplementation with 500 mg twice daily of a standardized extract of P. emblica (CAPROS) in obese adults 21 to 70 years of age with a BMI of 25 to 35. The significant effect on collagen-induced platelet aggregation was sustained beyond the 12 weeks of supplementation through the 2 week wash-out period, as well.94


Sperm count, motility, and viability were increased in mice and in human sperm with ripe emblica fruit extract.93


Few clinical studies with robust data to support benefit are available to guide dosage.


250 mg or 500 mg standardized extract of Phyllanthus embilica twice daily has been given for up to 12 weeks.94, 97, 98

Pregnancy / Lactation

Information regarding safety and efficacy in pregnancy and lactation is lacking.


None well documented.

Adverse Reactions

Research reveals little or no information regarding adverse reactions with the use of this product. Experiments in animals have shown no reported adverse reactions.


No major reported toxicities have been associated with the fruit. In toxicity studies in rats, no toxicity was observed in single- or longer-term–dose administration. Additionally, no detrimental effect was noted on liver or renal function.91 No chromosomal aberrations were found following 7- and 14-day treatment regimens in rats with crude fruit extract.48 In another experiment, no toxicity or mutagenicity were observed in rats even at the highest doses.44

Index Terms

  • Emblica officinalis Gaertn



This information relates to an herbal, vitamin, mineral or other dietary supplement. This product has not been reviewed by the FDA to determine whether it is safe or effective and is not subject to the quality standards and safety information collection standards that are applicable to most prescription drugs. This information should not be used to decide whether or not to take this product. This information does not endorse this product as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this product. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this product. This information is not specific medical advice and does not replace information you receive from your health care provider. You should talk with your health care provider for complete information about the risks and benefits of using this product.

This product may adversely interact with certain health and medical conditions, other prescription and over-the-counter drugs, foods, or other dietary supplements. This product may be unsafe when used before surgery or other medical procedures. It is important to fully inform your doctor about the herbal, vitamins, mineral or any other supplements you are taking before any kind of surgery or medical procedure. With the exception of certain products that are generally recognized as safe in normal quantities, including use of folic acid and prenatal vitamins during pregnancy, this product has not been sufficiently studied to determine whether it is safe to use during pregnancy or nursing or by persons younger than 2 years of age.

1. Phyllanthus emblica L. USDA, NRCS. 2007. PLANTS database. ( August 2006). National Plant Data Team, Greensboro, NC 27401-4901 USA.
2. Shanmugasundaram KR, Seethapathy PG, Shanmugasundaram ER. Anna Pavala Sindhooram–an antiatherosclerotic Indian drug. J Ethnopharmacol. 1983;7(3):247-265.6876850
3. Unander DW, Webster GL, Blumberg BS. Records of usage or assays in Phyllanthus (Euphorbiaceae). I. SubgeneraIsocladus, Kirganelia, Cicca and Emblica. J Ethnopharmacol. 1990;30(3):233-264.2259214
4. Nisha P, Singhal RS, Pandit AB. A study on degradation kinetics of ascorbic acid in amla (Phyllanthus emblica L.) during cooking. Int J Food Sci Nutr. 2004;55(5):415-422.15545050
5. Zhang YJ, Abe T, Tanaka T, Yang CR, Kouno I. Phyllanemblinins A-F, new ellagitannins from Phyllanthus emblica. J Nat Prod. 2001;64(12):1527-1532.11754604
6. Kumaran A, Karunakaran RJ. Nitric oxide radical scavenging active components from Phyllanthus emblica L. Plant Foods Hum Nutr. 2006;61(1):1-5.16688481
7. Zhang YJ, Nagao T, Tanaka T, Yang CR, Okabe H, Kouno I. Antiproliferative activity of the main constituents from Phyllanthus emblica. Biol Pharm Bull. 2004;27(2):251-255.14758047
8. Bajpai M, Pande A, Tewari SK, Prakash D. Phenolic contents and antioxidant activity of some food and medicinal plants. Int J Food Sci Nutr. 2005;56(4):287-291.16096138
9. Bhattacharya SK, Bhattacharya A, Sairam K, Ghosal S. Effect of bioactive tannoid principles of Emblica officinalis on ischemia-reperfusion-induced oxidative stress in rat heart. Phytomedicine. 2002;9(2):171-174.11995952
10. Anila L, Vijayalakshmi NR. Flavonoids from Emblica officinalis and Mangifera indica-effectiveness for dyslipidemia. J Ethnopharmacol. 2002;79(1):81-87.11744299
11. Zhang YJ, Tanaka T, Iwamoto Y, Yang CR, Kouno I. Novel norsesquiterpenoids from the roots of Phyllanthus emblica. J Nat Prod. 2000;63(11):1507-1510.11087593
12. Zhang YJ, Tanaka T, Iwamoto Y, Yang CR, Kouno I. Novel sesquiterpenoids from the roots of Phyllanthus emblica. J Nat Prod. 2001;64(7):870-873.11473414
13. Babu PS, Stanely Mainzen Prince P. Antihyperglycaemic and antioxidant effect of hyponidd, an ayurvedic herbomineral formulation in streptozotocin-induced diabetic rats. J Pharm Pharmacol. 2004;56(11):1435-1442.15525451
14. Rao TP, Sakaguchi N, Juneja LR, Wada E, Yokozawa T. Amla (Emblica officinalis Gaertn.) extracts reduce oxidative stress in streptozotocin-induced diabetic rats. J Med Food. 2005;8(3):362-368.16176148
15. Naik GH, Priyadarsini KI, Bhagirathi RG, et al. In vitro antioxidant studies and free radical reactions of triphala, an ayurvedic formulation and its constituents. Phytother Res. 2005;19(7):582-586.16161061
16. Naik GH, Priyadarsini KI, Mohan H. Evaluating the antioxidant activity of different plant extracts and herbal formulations. Res Chem Intermed. 2005;31(1-3):145-151.
17. Poltanov EA, Shikov AN, Dorman HJ, et al. Chemical and antioxidant evaluation of Indian gooseberry (Emblica officinalis Gaertn., syn. Phyllanthus emblica L.) supplements. Phytother Res. 2009;23(9):1309-1315.19172666
18. Scartezzini P, Speroni E. Review on some plants of Indian traditional medicine with antioxidant activity. J Ethnopharmacol. 2000;71(1-2):23-43.10904144
19. Dang GK, Parekar RR, Kamat SK, Scindia AM, Rege NN. Antiinflammatory activity of Phyllanthus emblica, Plumbago zeylanica and Cyperus rotundus in acute models of inflammation. Phytother Res. 2011;25(6):904-908.21132843
20. Muthuraman A, Sood S, Singla SK. The antiinflammatory potential of phenolic compounds from Emblica officinalis L. in rat. Inflammopharmacology. 2010 Jul 2. [Epub ahead of print]20596897
21. Nicolis E, Lampronti I, Dechecchi MC, et al. Pyrogallol, an active compound from the medicinal plant Emblica officinalis, regulates expression of pro-inflammatory genes in bronchial epithelial cells. Int Immunopharmacol. 2008;8(12):1672-1680.18760383
22. Sumantran VN, Kulkarni A, Chandwaskar R, et al. Chondroprotective potential of fruit extracts of Phyllanthus emblica in osteoarthritis. Evid Based Complement Alternat Med. 2008;5(3):329-335.18830448
23. Piva R, Penolazzi L, Borgatti M, et al. Apoptosis of human primary osteoclasts treated with molecules targeting nuclear factor-kappaB. Ann N Y Acad Sci. 2009;1171:448-456.19723088
24. Penolazzi L, Lampronti I, Borgatti M, et al. Induction of apoptosis of human primary osteoclasts treated with extracts from the medicinal plant Emblica officinalis. BMC Complement Altern Med. 2008;8:59.18973662
25. Rani P, Khullar N. Antimicrobial evaluation of some medicinal plants for their anti-enteric potential against multi-drug resistant Salmonella typhi. Phytother Res. 2004;18(8):670-673.15476301
26. Dutta BK, Rahman I, Das TK. Antifungal activity of Indian plant extracts. Mycoses. 1998;41(11-12):535-536.9919899
27. Rahman S, Akbor MM, Howlader A, Jabbar A. Antimicrobial and cytotoxic activity of the alkaloids of Amlaki (Emblica officinalis). Pak J Biol Sci. 2009;12(16):1152-1155.19899327
28. Liu X, Zhao M, Luo W, Yang B, Jiang Y. Identification of volatile components in Phyllanthus emblica L. and their antimicrobial activity. J Med Food. 2009;12(2):423-428.19459747
29. Xiang Y, Pei Y, Qu C, et al. In vitro Anti-Herpes Simplex Virus Activity of 1,2,4,6-Tetra-O-galloyl-beta-d-glucose from Phyllanthus emblica L. (Euphorbiaceae). Phytother Res. 2011 Jan 7. [Epub ahead of print]2121335510.1002/ptr.3368
30. Liu Q, Wang YF, Chen RJ, et al. Anti-coxsackie virus B3 norsesquiterpenoids from the roots of Phyllanthus emblica. J Nat Prod. 2009;72(5):969-972.19374435
31. Wang YF, Wang XY, Ren Z, et al. Phyllaemblicin B inhibits Coxsackie virus B3 induced apoptosis and myocarditis. Antiviral Res. 2009;84(2):150-158.19699238
32. Saini A, Sharma S, Chhibber S. Protective efficacy of Emblica officinalis against Klebsiella pneumoniae induced pneumonia in mice. Indian J Med Res. 2008;128(2):188-193.19001683
33. Biswas S, Talukder G, Sharma A. Protection against cytotoxic effects of arsenic by dietary supplementation with crude extract of Emblica officinalis fruit. Phytother Res. 1999;13(6):513-516.10479764
34. Sai Ram M, Neetu D, Deepti P, et al. Cytoprotective activity of Amla (Emblica officinalis) against chromium (VI) induced oxidative injury in murine macrophages. Phytother Res. 2003;17(4):430-433.12722158
35. Sai Ram M, Neetu D, Yogesh B, et al. Cyto-protective and immunomodulating properties of Amla (Emblica officinalis) on lymphocytes: an in-vitro study. J Ethnopharmacol. 2002;81(1):5-10.12020921
36. Dhir H, Agarwal K, Sharma A, Talukder G. Modifying role of Phyllanthus emblica and ascorbic acid against nickel clastogenicity in mice. Cancer Lett. 1991;26;59(1):9-18.1878862
37. Jeena KJ, Joy KL, Kuttan R. Effect of Emblica officinalis, Phyllanthus amarus and Picrorrhiza kurroa on N-nitrosodiethylamine induced hepatocarcinogenesis. Cancer Lett. 1999;136(1):11-16.10211933
38. Suresh K, Vasudevan DM. Augmentation of murine natural killer cell and antibody dependent cellular cytotoxicity activities by Phyllanthus emblica, a new immunomodulator. J Ethnopharmacol. 1994;44(1):55-60.7990505
39. Veena K, Shanthi P, Sachdanandam P. Anticancer effect of Kalpaamurthaa on mammary carcinoma in rats with reference to glycoprotein components, lysosomal and marker enzymes. Biol Pharm Bull. 2006:29(3):565-569.16508169
40. Menon LG, Kuttan R, Kuttan G. Effect of rasayanas in the inhibition of lung metastasis induced by B16F-10 melanoma cells. J Exp Clin Cancer Res. 1997;16(4):365-368.9505206
41. Singh I, Sharma A, Nunia V, Goyal PK. Radioprotection of Swiss albino mice by Emblica officinalis. Phytother Res. 2005;19(5):444-446.16106381
42. Jagetia GC, Baliga MS, Malagi KJ, Kamath M. The evaluation of the radioprotective effect of Triphala (an ayurvedic rejuvenating drug) in the mice exposed to gamma-radiation. Phytomedicine. 2002;9(2):99-108.11995956
43. Jindal A, Soyal D, Sharma A, Goyal PK. Protective effect of an extract of Emblica officinalis against radiation-induced damage in mice. Integr Cancer Ther. 2009;8(1):98-105.19223372
44. Sharma N, Trikha P, Athar M, Raisuddin S. In vitro inhibition of carcinogen-induced mutagenicity by Cassia occidentalis and Emblica officinalis. Drug Chem Toxicol. 2000;23(3):477-484.10959548
45. Arora S, Kaur K, Kaur S. Indian medicinal plants as a reservoir of protective phytochemicals. Teratog Carcinog Mutagen. 2003;(suppl 1):295-300.12616620
46. Yang CJ, Wang CS, Hung JY, et al. Pyrogallol induces G2-M arrest in human lung cancer cells and inhibits tumor growth in an animal model. Lung Cancer. 2009;66(2):162-168.19233505
47. Ngamkitidechakul C, Jaijoy K, Hansakul P, Soonthornchareonnon N, Sireeratawong S. Antitumour effects of Phyllanthus emblica L.: induction of cancer cell apoptosis and inhibition of in vivo tumour promotion and in vitro invasion of human cancer cells. Phytother Res. 2010;24(9):1405-1143.20812284
48. Jose JK, Kuttan G, Kuttan R. Antitumour activity of Emblica officinalis. J Ethnopharmacol. 2001;75(2-3):65-69.11297836
49. Pinmai K, Chunlaratthanabhorn S, Ngamkitidechakul C, Soonthornchareon N, Hahnvajanawong C. Synergistic growth inhibitory effects of Phyllanthus emblica and Terminalia bellerica extracts with conventional cytotoxic agents: doxorubicin and cisplatin against human hepatocellular carcinoma and lung cancer cells. World J Gastroenterol. 2008;14(10):1491-1497.18330936
50. Zhong ZG, Wu DP, Huang JL, et al. Progallin A isolated from the acetic ether part of the leaves of Phyllanthus emblica L. induces apoptosis of human hepatocellular carcinoma BEL-7404 cells by up-regulation of Bax expression and down-regulation of Bcl-2 expression. J Ethnopharmacol. 2011;133(2):765-772.21073944
51. Sultana S, Ahmed S, Jahangir T. Emblica officinalis and hepatocarcinogenesis: a chemopreventive study in Wistar rats. J Ethnopharmacol. 2008:19;118(1):1-6.18467048
52. Sumitra M, Manikandan P, Gayathri VS, Mahendran P, Suguna L. Emblica officinalis exerts wound healing action through up-regulation of collagen and extracellular signal-regulated kinases (ERK1/2). Wound Repair Regen. 2009;17(1):99-107.19152656
53. Fujii T, Wakaizumi M, Ikami T, Saito M. Amla (Emblica officinalis Gaertn.) extract promotes procollagen production and inhibits matrix metalloproteinase-1 in human skin fibroblasts. J Ethnopharmacol. 2008;119(1):53-57.18588964
54. Adil MD, Kaiser P, Satti NK, Zargar AM, Vishwakarma RA, Tasduq SA. Effect of Emblica officinalis (fruit) against UVB-induced photo-aging in human skin fibroblasts. J Ethnopharmacol. 2010;132(1):109-114.20688142
55. Costa A, Moisés TA, Cordero T, Alves CR, Marmirori J. Association of emblica, licorice and belides as an alternative to hydroquinone in the clinical treatment of melasma. An Bras Dermatol. 2010;85(5):613-620.21152784
56. Al-Rehaily AJ, Al-Howiriny TA, Al-Sohaibani MO, Rafatullah S. Gastroprotective effects of "Amla" Emblica officinalis on in vivo test models in rats. Phytomedicine. 2002;9(6):515-522.12403160
57. Sairam K, Rao ChV, Babu MD, Kumar KV, Agrawal VK, Goel RK. Antiulcerogenic effect of methanolic extract of Emblica officinalis: an experimental study. J Ethnopharmacol. 2002;82(1):1-9.12169398
58. Bandyopadhyay SK, Pakrashi SC, Pakrashi A. The role of antioxidant activity of Phyllanthus emblica fruits on prevention from indomethacin induced gastric ulcer. J Ethnopharmacol. 2000;70(2):171-176.10771207
59. Chatterjee A, Chattopadhyay S, Bandyopadhyay SK. Biphasic Effect of Phyllanthus emblica L. Extract on NSAID-Induced Ulcer: An Antioxidative Trail Weaved with Immunomodulatory Effect. Evid Based Complement Alternat Med. 2011;2011:146808. Epub 2010 Nov 7.21076542
60. Mehmood MH, Siddiqi HS, Gilani AH. The antidiarrheal and spasmolytic activities of Phyllanthus emblica are mediated through dual blockade of muscarinic receptors and Ca2+ channels. J Ethnopharmacol. 2011;133(2):856-865.21093572
61. Tasduq SA, Kaisar P, Gupta DK, et al. Protective effect of a 50% hydroalcoholic fruit extract of Emblica officinalis against anti-tuberculosis drugs induced liver toxicity. Phytother Res. 2005;19(3):193-197.15934014
62. Tasduq SA, Mondhe DM, Gupta DK, Baleshwar M, Johri RK. Reversal of fibrogenic events in liver by Emblica officinalis (fruit), an Indian natural drug. Biol Pharm Bull. 2005;28(7):1304-1306.15997120
63. Haque R, Bin-Hafeez B, Ahmad I, Parvez S, Pandey S, Raisuddin S. Protective effects of Emblica officinalis Gaertn. in cyclophosphamide-treated mice. Hum Exp Toxicol. 2001;20(12):643-650.11936579
64. Jose JK, Kuttan R. Hepatoprotective activity of Emblica officinalis and Chyavanaprash. J Ethnopharmacol. 2000;72(1-2):135-140.10967464
65. Sultana S, Ahmed S, Sharma S, Jahangir T. Emblica officinalis reverses thioacetamide-induced oxidative stress and early promotional events of primary hepatocarcinogenesis. J Pharm Pharmacol. 2004;56(12):1573-1579.15586980
66. Pramyothin P, Samosorn P, Poungshompoo S, Chaichantipyuth C. The protective effects of Phyllanthus emblica Linn. extract on ethanol induced rat hepatic injury. J Ethnopharmacol. 2006;107(3):361-364.16750340
67. Verma R, Chakraborty D. Alterations in DNA, RNA and protein contents in liver and kidney of mice treated with ochratoxin and their amelioration by Emblica officinalis aqueous extract. Acta Pol Pharm. 2008;65(1):3-9.18536167
68. Chakraborty D, Verma R. Ameliorative effect of Emblica officinalis aqueous extract on ochratoxin-induced lipid peroxidation in the kidney and liver of mice. Int J Occup Med Environ Health. 2010;23(1):63-73.20442064
69. Sharma A, Sharma MK, Kumar M. Modulatory role of Emblica officinalis fruit extract against arsenic induced oxidative stress in Swiss albino mice. Chem Biol Interact. 2009;180(1):20-30.19428342
70. Reddy VD, Padmavathi P, Varadacharyulu NCh. Emblica officinalis protects against alcohol-induced liver mitochondrial dysfunction in rats. J Med Food. 2009;12(2):327-333.19459733
71. Sidhu S, Pandhi P, Malhotra S, Vaiphei K, Khanduja KL. Beneficial effects of Emblica officinalis in L-arginine-induced acute pancreatitis in rats. J Med Food. 2011;14(1-2):147-155.21138365
72. Chen TS, Liou SY, Chang YL. Supplementation of Emblica officinalis (Amla) extract reduces oxidative stress in uremic patients. Am J Chin Med. 2009;37(1):19-25.19222108
73. Anila L, Vijayalakshmi NR. Beneficial effects of flavonoids from Sesamum indicum, Emblica officinalis and Momordica charantia. Phytother Res. 2000;14(8):592-595.11113993
74. Kim HY, Okubo T, Juneja LR, Yokozawa T. The protective role of amla ( Emblica officinalis Gaertn.) against fructose-induced metabolic syndrome in a rat model. Br J Nutr. 2010;103(4):502-512.19878614
75. Yokozawa T, Kim HY, Kim HJ, Okubo T, Chu DC, Juneja LR. Amla (Emblica officinalis Gaertn.) prevents dyslipidaemia and oxidative stress in the ageing process. Br J Nutr. 2007;97(6):1187-1195.17506915
76. Mathur R, Sharma A, Dixit VP, Varma M. Hypolipidaemic effect of fruit juice of Emblica officinalis in cholesterol-fed rabbits. J Ethnopharmacol. 1996;50(2):61-68.8866725
77. Jacob A, Pandey M, Kapoor S, Saroja R. Effect of the Indian gooseberry (amla) on serum cholesterol levels in men aged 35-55 years. Eur J Clin Nutr. 1988;42(11):939-944.3250870
78. Akhtar MS, Ramzan A, Ali A, Ahmad M. Effect of Amla fruit (Emblica officinalis Gaertn.) on blood glucose and lipid profile of normal subjects and type 2 diabetic patients. Int J Food Sci Nutr. 2011 Apr 18. [Epub ahead of print]21495900
79. Sabu MC, Kuttan R. Anti-diabetic activity of medicinal plants and its relationship with their antioxidant property. J Ethnopharmacol. 2002;81(2):155-160.12065146
80. Tiwari V, Kuhad A, Chopra K. Emblica officinalis Corrects Functional, Biochemical and Molecular Deficits in Experimental Diabetic Neuropathy by Targeting the Oxido-nitrosative Stress Mediated Inflammatory Cascade. Phytother Res. 2011 Mar 11. [Epub ahead of print]2139480510.1002/ptr.3440
81. Nampoothiri SV, Prathapan A, Cherian OL, Raghu KG, Venugopalan VV, Sundaresan A. In vitro antioxidant and inhibitory potential of Terminalia bellerica and Emblica officinalis fruits against LDL oxidation and key enzymes linked to type 2 diabetes. Food Chem Toxicol. 2011;49(1):125-131.20951180
82. Suryanarayana P, Saraswat M, Petrash JM, Reddy GB. Emblica officinalis and its enriched tannoids delay streptozotocin-induced diabetic cataract in rats. Mol Vis. 2007;13:1291-1297.17679931
83. Perianayagam JB, Sharma SK, Joseph A, Christina AJ. Evaluation of anti-pyretic and analgesic activity of Emblica officinalis Gaertn. J Ethnopharmacol. 2004;95(1):83-85.15374611
84. Nosál'ová G, Mokrý J, Hassan KM. Antitussive activity of the fruit extract of Emblica officinalis Gaertn. (Euphorbiaceae). Phytomedicine. 2003;10(6-7):583-589.13678247
85. Alam MI, Gomes A. Snake venom neutralization by Indian medicinal plants (Vitex negundo and Emblica officinalis) root extracts. J Ethnopharmacol. 2003;86(1):75-80.12686445
86. Rajak S, Banerjee SK, Sood S, et al. Emblica officinalis causes myocardial adaptation and protects against oxidative stress in ischemic-reperfusion injury in rats. Phytother Res. 2004;18(1):54-60.14750202
87. Vasudevan M, Parle M. Effect of Anwala churna (Emblica officinalis GAERTN.): an ayurvedic preparation on memory deficit rats. Yakugaku Zasshi. 2007;127(10):1701-1707.17917427
88. Vasudevan M, Parle M. Memory enhancing activity of Anwala churna ( Emblica officinalis Gaertn.): an Ayurvedic preparation. Physiol Behav. 2007;91(1):46-54.17343883
89. Reddy VD, Padmavathi P, Kavitha G, Gopi S, Varadacharyulu N. Emblica officinalis ameliorates alcohol-induced brain mitochondrial dysfunction in rats. J Med Food. 2011;14(1-2):62-68.21138366
90. Srikumar R, Parthasarathy NJ, Manikaordan S, Narayanan GS, Sheeladevi R. Effect of Triphala on oxidative stress and on cell-mediated immune response against noise stress in rats. Mol Cell Biochem. 2006;283(1-2):67-74.16444587
91. Rege NN, Thatte UM, Dahanukar SA. Adaptogenic properties of six rasayana herbs used in Ayurvedic medicine. Phytother Res. 1999;13(4):275-291.10404532
92. Biswas NR, Gupta SK, Das GK, et al. Evaluation of Ophthacare eye drops — a herbal formulation in the management of various ophthalmic disorders. Phytother Res. 2001;15(7):618-620.11746845
93. Chakraborty D, Verma R. Spermatotoxic effect of ochratoxin and its amelioration by Emblica officinalis aqueous extract. Acta Pol Pharm. 2009;66(6):689-695.20050533
94. Khanna S, Das A, Speildenner J, Rink C, Roy S. Supplementation for a standardized extract from Phyllanthus emblica improves cardiovascular risk factors and platelet aggregation in overweight/class-1 obese adults. J Med Food. 2015;18(4):415-420.25756303
95. Gao Q, Li X, Huang H, Guan Y, Mi Q, Yao J. The efficacy of a chewing cum containing Phyullanthus emblica fruit extract in improving oral health. Current Microbiol. 2018;75(5):604-610.29564547
96. Grover S, Tewari S, Sharma RK, Singh G, Yadav A, Naula SC. Effect of subgingivally delivered 10% Emblica officinalis gel as an adjunct to scaling and root planing in the treatment of chronic periodontitis – a randomized placebo-controlled clinical trial. Phytother Res. 2016;30(6):956-962.26914986
97. Upadya H, Prabhu S, Prasad A, Subramanian D, Gupta S, Goel A. A randomized, double blind, placebo controlled, multicenter clinical trial to assess the efficacy and safety of Emblica officinalis extract in patients with dyslipidemia. BMC Complement Altern Med. 2019;19(1):2730670010
98. Usharani P, Merugu PL, Nutalapati C. Evaluation of the effects of a standardized aqueous extract of Phyllanthus emblica fruits on endothelial dysfunction, oxidative stress, systemic inflammation and lipid profile in subjects with metabolic syndrome: a randomised, double blind, placebo controlled clinical study. BMC Complement Altern Med. 2019;19(1):97.31060549

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.